Biofrontera warrants face Nasdaq delisting notice

Biofrontera Inc.'s warrants are the subject of a Nasdaq Stock Market LLC Form 25 notice concerning removal from listing and/or registration under Section 12(b) of the Securities Exchange Act of 1934.

Available on EDGAR 10/30/2026 - 04:06 PM EDT Accepted by SEC EDGAR 10/30/2026 - 04:06 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Biofrontera Inc.'s warrants are the subject of a Nasdaq Stock Market LLC Form 25 notice concerning removal from listing and/or registration under Section 12(b) of the Securities Exchange Act of 1934. Nasdaq certified that it had reasonable grounds to believe it met the requirements for filing the notice.

Key Terms

Form 25, Section 12(b), withdraw registration

3 terms

Form 25 regulatory

"FORM 25 NOTIFICATION OF REMOVAL FROM LISTING"

A Form 25 is an official filing with the U.S. Securities and Exchange Commission used to remove a company's stock or other security from a national exchange list. Investors should care because delisting often means less visibility, lower trading volume and wider price swings—similar to a product moving from a major supermarket to a small local market, which can make buying, selling and valuing the security more difficult.

Section 12(b) regulatory

"under Section 12(b) of the Securities Exchange Act of 1934"

Section 12(b) of the U.S. Securities Exchange Act requires securities listed on a national stock exchange to be registered with the U.S. Securities and Exchange Commission (SEC) and to follow regular public reporting and disclosure rules. For investors, a 12(b) listing generally means more routine financial updates, regulatory oversight and easier buying and selling—like a storefront that must display its inventory and prices, making it simpler to inspect and trade the product.

withdraw registration regulatory

"withdraw registration on the Exchange"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

Which BFRI securities are covered by the Nasdaq Form 25 notice?

The notice concerns Biofrontera Inc.'s warrants and their removal from Nasdaq listing and/or Section 12(b) registration.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

UNITED STATES

OMB APPROVAL

OMB Number:			3235-0080
Expires:	March 31, 2018
Estimated average burden
hours per response:			1.7

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 25

NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION
UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934.

Commission File Number

001-40943

Issuer:	Biofrontera Inc.
Exchange:	Nasdaq Stock Market LLC

(Exact name of Issuer as specified in its charter, and name of Exchange where security is listed and/or registered)

Address:	120 Presidential Way, Suite 330
	Woburn	MASSACHUSETTS	01801
Telephone number:					781-245-1325

(Address, including zip code, and telephone number, including area code, of Issuer's principal executive offices)

warrant

(Description of class of securities)

Please place an X in the box to designate the rule provision relied upon to strike the class of securities from listing and registration:

17 CFR 240.12d2-2(a)(1)

17 CFR 240.12d2-2(a)(2)

17 CFR 240.12d2-2(a)(3)

17 CFR 240.12d2-2(a)(4)

Pursuant to 17 CFR 240.12d2-2(b), the Exchange has complied with its rules to strike the class of securities from listing and/or withdraw registration on the Exchange. ¹

Pursuant to 17 CFR 240.12d2-2(c), the Issuer has complied with its rules of the Exchange and the requirements of 17 CFR 240.12d-2(c) governing the voluntary withdrawal of the class of securities from listing and registration on the Exchange.

Pursuant to the requirements fo the Securities Exchange Act of 1934, Nasdaq Stock Market LLC certifies that it has reasonable grounds to believe that it meets all of the requirements for filing the Form 25 and has caused this notification to be signed on its behalf by the undersigned duly authorized person.

2026-10-30	By	Tara Petta		AVP
Date		Name		Title

¹ Form 25 and attached Notice will be considered compliance with the provisions of 17 CFR 240.19d-1 as applicable. See General Instructions.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.